Pascal Egloff.


Pascal Egloff is one of the founders of Linkster Therapeutics.

Pascal has more than 11 years of experience in the GPCR and antibody engineering field. Prior to co-founding Linkster Therapeutics, Pascal worked with renowned names at Stanford, Harvard and Zurich including William Weiss, Gerhard Wagner and Andreas Plückthun. At University of Zurich, he was engaged as platform leader for tissue-specific delivery. He co-invented the Flycode and Sybody technologies and lead discovery projects with major pharma and research institutes in Europe and USA. 

Pascal holds a master and PhD degree in Biochemistry from ETH Zurich and University of Zurich, respectively. He was awarded the Swiss Bridge Foundation award for advancements in tumor targeting.